Prostate cancer is the most common non-skin malignancy diagnosed in men in the United States and is a leading cause of cancer-related morbidity and mortality worldwide [1]. Early detection relies primarily on prostate-specific antigen (PSA) testing, with histopathologic confirmation obtained through transrectal or transperineal prostate biopsy [1]. This evidence concerns the gene KLK3 and prostate cancer.